ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk ...Middle East

New ESC guidelines recommend using both an SGLT2 inhibitor and a GLP-1 receptor agonist simultaneously to treat people with type 2 diabetes and established cardiovascular disease. Medscape Medical News

Hence then, the article about esc backs sglt2i plus glp 1 in diabetes with high cvd risk was published today ( Sunday 27/08/2023 - 01:08 AM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk )

Also on site :

• Werk Room Weekly: Briar Blush faints on-stage, beefs with Mia Starr, more .. ‘Drag Race’ S18 E4 Recap
• Robert Reed’s Daughter, Who Appeared on 'The Brady Bunch', Dies at 69
• ‘Change is inevitable’: What is next for Iran?